Free tool
Oncology stocks
We cover 80 companies grouped under the Oncology theme. The median market value in the group is $121.50M. Across the group, the median move over the past trading day is 0.00%. 44% of the 71 with a 200-day average trade above it. Price change over the past year runs from −75.1% to +138.8% across the middle 80 percent of the group, with a median of −5.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
80 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% |
| AZN.L | AstraZeneca PLC | 12,110.00 GBP | −6.41% | −10.89% | +1.98% |
| GE9.DE | GENMAB AS N | 283.30 EUR | +10.97% | +5.71% | −14.41% |
| 0J9P.L | Incyte Corporation | $130.13 | +1.97% | +30.41% | +53.55% |
| IPN.PA | Ipsen S.A. | 162.60 EUR | +1.37% | +40.05% | +39.21% |
| 0IJO.L | Exelixis, Inc. | $56.16 | +3.33% | +30.00% | +44.33% |
| 0M2N.L | Orion Oyj | 80.50 EUR | +12.46% | +29.29% | +19.68% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $122.59 | −2.12% | +233.46% | +75.99% |
| HCM.L | HUTCHMED (China) Limited | 178.00 GBP | +0.85% | −12.75% | −21.24% |
| NANO.PA | Nanobiotix S.A. | 34.14 EUR | +3.96% | +79.68% | +341.09% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.41% | −12.36% | −44.50% |
| 0HFQ.L | AnaptysBio, Inc. | $56.87 | −3.20% | +24.44% | +183.92% |
| PHIL.MI | Philogen S.p.A. | 23.35 EUR | −2.71% | +3.88% | +2.12% |
| EUZ.DE | Eckert & Ziegler SE | 13.65 EUR | −0.29% | −9.06% | −23.06% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $11.16 | +4.01% | +42.04% | +5.13% |
| 0QAV.L | Nanobiotix S.A. | 34.51 EUR | −2.83% | +80.19% | +346.30% |
| 0KCS.L | OPKO Health, Inc. | $1.51 | +2.03% | +16.20% | +5.63% |
| 0IL8.L | Kyntra Bio, Inc. | $7.95 | +1.50% | −11.24% | −24.41% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.02 EUR | −0.97% | −91.09% | −91.09% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.79 EUR | +5.76% | +374.47% | +1150.00% |
| 0LOV.L | Verastem, Inc. | $7.14 | +3.48% | −1.92% | −21.47% |
| AVCT.L | Avacta Group Plc | 68.80 GBP | +0.44% | +19.65% | +32.31% |
| PRTC.L | PureTech Health plc | 118.80 GBP | +0.51% | −4.65% | −11.34% |
| 0XOD.L | UroGen Pharma Ltd. | $46.35 | −1.31% | +105.18% | +136.32% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.40% | −15.23% | −16.98% |
| 0IV3.L | Geron Corporation | $1.54 | 0.00% | +16.67% | +8.41% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +17.37% | +16.21% | +1.84% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +4.07% | −17.21% | −24.30% |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.59% |
| HPHA.DE | Heidelberg Pharma AG | 2.53 EUR | −1.17% | +1.20% | −44.40% |
| SCLP.L | Scancell Holdings plc | 9.80 GBP | −1.51% | −1.01% | −6.67% |
| 0RU5.L | Oncoinvent ASA | 70.20 NOK | −18.37% | +61.75% | +5951.72% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 72.40 PLN | −2.95% | −3.47% | +76.16% |
| 0RDB.L | Oryzon Genomics S.A. | 2.84 EUR | +0.92% | −11.03% | +4.08% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.80 PLN | +25.33% | −30.76% | −34.72% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −80.71% |
| OSE.PA | OSE Immunotherapeutics SA | 3.19 EUR | +0.69% | −39.85% | −47.82% |
| 0QW5.L | Heidelberg Pharma AG | 2.46 EUR | +3.36% | −2.38% | −45.58% |
| 0J4V.L | Heron Therapeutics, Inc. | $0.32 | +1.38% | −74.92% | −76.73% |
| POLB.L | Poolbeg Pharma PLC | 8.50 GBP | +38.21% | +117.95% | +161.54% |
| 0QXX.L | Molecular Partners AG | 3.51 CHF | +2.33% | +3.54% | +22.73% |
| SAR.L | Sareum Holdings plc | 29.00 GBP | +31.82% | +70.59% | +38.10% |
| MAAT.PA | MaaT Pharma SA | 3.05 EUR | +8.75% | −45.43% | −39.58% |
| 0OCQ.L | Transgene SA | 0.81 EUR | −0.25% | −16.36% | −18.38% |
| COIL.L | Coiled Therapeutics plc | 9.50 GBP | −5.00% | −20.83% | −26.92% |
| 0RAD.L | OSE Immunotherapeutics SA | 3.16 EUR | −2.11% | −40.40% | −48.92% |
| CANTA.ST | Cantargia AB (publ) | 1.90 SEK | +1.71% | −53.86% | −28.93% |
| SVE.WA | Synthaverse S.A. | 3.04 PLN | +10.55% | −20.73% | −37.70% |
| MOC.WA | Molecure S.A. | 6.14 PLN | +2.33% | −6.40% | −21.18% |
| NNG.WA | NanoGroup S.A. | 2.47 PLN | +2.28% | −7.84% | −14.09% |
| DEX.ST | DexTech Medical AB | 10.40 SEK | −0.95% | +12.43% | +20.93% |
| B8FK.DE | Biofrontera AG | 2.52 EUR | −1.95% | −1.18% | −4.55% |
| ABERA.ST | Abera Bioscience AB | 8.14 SEK | −7.29% | +13.06% | −0.12% |
| ACTI.ST | Active Biotech AB (publ) | 5.55 SEK | +7.77% | +20.65% | −60.62% |
| ALTME.PA | TME Pharma N.V. | 0.16 EUR | +147.62% | +126.09% | +48.57% |
| CRTX.L | CRISM Therapeutics Corporation | 11.50 GBP | +21.05% | +15.00% | +9.52% |
| 0NWK.L | Valerio Therapeutics Société anonyme | 0.82 EUR | +3.03% | +393.94% | +1214.52% |
| PUR.WA | MultiQure S.A. | 3.14 PLN | +45.81% | −23.35% | −53.66% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | 0.32 EUR | +1.26% | −17.65% | −17.01% |
| CHOSA.ST | CHOSA Oncology AB | 0.73 SEK | −14.59% | −20.22% | −12.00% |
| 0GP7.L | Medivir AB (publ) | 2.08 SEK | +9.14% | +355.54% | +3.85% |
| NFX.L | Nuformix plc | 0.17 GBP | +3.13% | −44.07% | +106.25% |
| DBP-B.ST | Double Bond Pharmaceutical Int. | 0.15 SEK | +18.62% | +9.33% | +9.33% |
| VAL.L | ValiRx plc | 0.16 GBP | −3.13% | −57.53% | −73.04% |
| 0RK9.L | Alligator Bioscience AB (publ) | 0.03 SEK | −1.31% | −91.40% | −99.22% |
| ATORX.ST | Alligator Bioscience AB (publ) | 0.03 SEK | −28.13% | −91.12% | −99.30% |
| PTP.DE | Pentixapharm Holding AG N | 1.88 EUR | −4.57% | +22.08% | +8.55% |
| 0GQU.L | Active Biotech AB (publ) | 5.46 SEK | +5.61% | +7801.59% | +7801.59% |
| 0A4Y.L | AIM ImmunoTech Inc. | $0.26 | +1.64% | −78.46% | −89.57% |
| 0GHZ.L | Xspray Pharma AB (publ) | 10.87 SEK | +1.75% | −56.52% | −74.90% |
| 0HL9.L | Affimed N.V. | $0.00 | 0.00% | 0.00% | 0.00% |
| 0HS8.L | Lisata Therapeutics, Inc. | $1.76 | +0.57% | −6.38% | −29.74% |
| 0J7G.L | HUTCHMED (China) Limited | $12.31 | +9.91% | +8.47% | +8.47% |
| 0K2H.L | Moleculin Biotech, Inc. | $0.65 | +8.76% | −80.36% | −95.38% |
| 0LC7.L | Syros Pharmaceuticals, Inc. | $0.00 | 0.00% | −50.00% | −90.91% |
| 0VQ.DE | PureTech Health plc | 1.35 EUR | 0.00% | −12.90% | +1.50% |
| CURAS.CO | Curasight A/S | 15.15 DKK | −12.43% | −36.88% | −36.88% |
| MOLN.SW | Molecular Partners AG | 3.53 CHF | +12.06% | +4.13% | +18.66% |
| T9G.DE | Vidac Pharma Holding Plc | 0.43 EUR | −6.97% | −37.21% | −37.21% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.